Skip to main content
Grade AHigh Confidence

Evidence Grade A

Replicated findings across multiple well-designed studies

What Grade A Means

Grade A represents our highest level of confidence in a research finding. These are claims supported by replicated findings across multiple well-designed studies, typically including randomized controlled trials (RCTs) or large prospective cohort studies that have been independently verified.

  • Multiple research teams have tested this claim
  • Results have been replicated in different populations
  • Study designs minimize bias and confounding
  • The scientific community broadly accepts these findings

Criteria for Grade A Classification

A finding receives Grade A status when it meets all of the following:

1. Replication Across Studies

The finding has been reproduced by independent research teams. A single study — no matter how well-designed — cannot achieve Grade A. We require at least 2-3 confirmatory studies from different institutions.

2. Robust Study Design

Supporting studies include randomized controlled trials (RCTs), large prospective cohort studies (n > 1,000), or systematic reviews/meta-analyses of quality studies.

3. Consistent Effect Direction

Results point in the same direction across studies. Minor variations in effect size are expected, but the fundamental finding remains consistent.

4. Biological Plausibility

The finding aligns with established physiological mechanisms. Surprising results require stronger replication evidence.

5. Clinical Validation

Where applicable, the finding correlates with clinical outcomes (disease incidence, mortality, symptom resolution) — not just biomarker changes.

What Grade A Does NOT Mean

Grade A does not mean "absolute truth." Even our highest-confidence findings carry uncertainty. Science is provisional by nature.

Grade A means:

  • This is the best available evidence
  • Multiple studies agree
  • You can reasonably rely on this information

Grade A does NOT mean:

  • This will never be revised
  • This applies to every individual equally
  • No exceptions exist

Examples of Grade A Evidence on Metabolicum

TG/HDL Ratio and Insulin Resistance

TG/HDL ratio ≥3.0 identifies insulin-resistant individuals with approximately 79% sensitivity.

Supporting Evidence:

  • McLaughlin et al., 2003 (Ann Intern Med) — Original validation in 258 subjects
  • McLaughlin et al., 2005 (Am J Cardiol) — Confirmed across different body weights
  • Gaziano et al., 1997 (Circulation) — Cardiovascular outcome correlation in 14,916 men
  • Salazar et al., 2013 — Superior to metabolic syndrome criteria

Why Grade A: Replicated across multiple populations, different research teams, consistent direction, validated against gold-standard insulin clamp measurements.

HOMA-IR Formula Validity

HOMA-IR correlates strongly (r ≈ 0.82) with the euglycemic clamp method for measuring insulin resistance.

Supporting Evidence:

  • Matthews et al., 1985 (Diabetologia) — Original formula derivation and validation
  • Wallace et al., 2004 (Diabetes Care) — Comprehensive review confirming appropriate use
  • Multiple subsequent validation studies across populations

Why Grade A: The formula has been validated against the gold standard across thousands of subjects over 40 years. It's the most widely used insulin resistance assessment in clinical research.

WHtR 0.5 Threshold

Waist-to-height ratio below 0.5 is associated with lower cardiometabolic risk across diverse populations.

Supporting Evidence:

  • Ashwell & Hsieh, 2005 — Established universal threshold rationale
  • Browning et al., 2010 (Nutr Res Rev) — Systematic review confirming 0.5 across 78 studies
  • Meta-analysis of 300,000+ participants

Why Grade A: Systematic review with massive sample size, consistent across ethnicities, ages, and sexes.

How We Use Grade A Evidence

On Metabolicum, Grade A evidence forms the foundation of our:

Calculator thresholds

Primary cutoffs come from Grade A sources

Core educational claims

Statements presented as established fact

Risk categorizations

How we label results (optimal, elevated, high)

When multiple Grade A sources suggest different thresholds, we present the range and explain the variation rather than arbitrarily choosing one value.

Limitations to Keep in Mind

Population Specificity

Most research is conducted in Western populations. Findings may not apply equally to all ethnicities. We note population limitations where known.

Individual Variation

Population-level findings describe averages. Your individual response may differ due to genetics, environment, and other factors.

Evolving Science

Grade A findings can be revised as new evidence emerges. We update our content when the science changes.

Context Matters

A Grade A finding about insulin resistance in overweight adults may not apply to lean individuals, athletes, or those with specific medical conditions.

Grade A Citations on Metabolicum (17)

Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE (1997)

Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction

Circulation

Key finding: TG/HDL ratio was the strongest predictor of myocardial infarction among all lipid measures examined

View on PubMed

McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G (2003)

Use of metabolic markers to identify overweight individuals who are insulin resistant

Annals of Internal Medicine

Key finding: TG/HDL ratio ≥3.0 identified insulin-resistant individuals with 79% sensitivity and 65% specificity

View on PubMed

McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, Simon J, Krauss RM (2005)

Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?

American Journal of Cardiology

Key finding: TG/HDL ratio identified insulin resistance regardless of body weight

View on PubMed

Hanak V, Munoz J, Teague J, Stanley A Jr, Bittner V (2004)

Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B

American Journal of Cardiology

Key finding: TG/HDL ratio of 3.8 predicted LDL phenotype B (small, dense) with 79% sensitivity and 81% specificity

View on PubMed

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985)

Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man

Diabetologia

Key finding: Established HOMA-IR formula and validated against euglycemic clamp

View on PubMed

Wallace TM, Levy JC, Matthews DR (2004)

Use and abuse of HOMA modeling

Diabetes Care

Key finding: Comprehensive review of HOMA validation and appropriate use

View on PubMed

Hallberg SJ, McKenzie AL, Williams PT, Bhanpuri NH, Peters AL, et al. (2018)

Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year

Diabetes Therapy

Key finding: TG/HDL ratio improved by 29%, HOMA-IR improved by 55%, HbA1c reduced from 7.6% to 6.3%

View on PubMed

Athinarayanan SJ, Adams RN, Hallberg SJ, McKenzie AL, Bhanpuri NH, et al. (2019)

Long-term effects of a novel continuous remote care intervention including nutritional ketosis for the management of type 2 diabetes: a 2-year non-randomized clinical trial

Frontiers in Endocrinology

Key finding: 2-year sustainability of metabolic improvements

View on PubMed

Choi YJ, Jeon SM, Shin S (2020)

Impact of a ketogenic diet on metabolic parameters in patients with obesity or overweight and with or without type 2 diabetes: a meta-analysis of randomized controlled trials

Nutrients

Key finding: Significant TG reduction and HDL increase across 14 RCTs

View on PubMed

Yuan X, Wang J, Yang S, Gao M, Cao L, Li X, Hong D, Tian S, Sun C (2020)

Effect of the ketogenic diet on glycemic control, insulin resistance, and lipid metabolism in patients with T2DM: a systematic review and meta-analysis

Nutrition & Diabetes

Key finding: TG decreased by 0.72 mmol/L, HDL increased by 0.14 mmol/L

View on PubMed

Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S (1998)

The metabolically obese, normal-weight individual revisited

Diabetes

Key finding: Established MONW (metabolically obese normal weight) as clinical entity

View on PubMed

Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, et al. (2008)

The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering

Archives of Internal Medicine

Key finding: 23.5% of normal-weight adults were metabolically abnormal

View on PubMed

Ashwell M, Hsieh SD (2005)

Six reasons why the waist-to-height ratio is a rapid and effective global indicator for health risks of obesity

International Journal of Food Sciences and Nutrition

Key finding: WHtR <0.5 as universal threshold across populations

View on PubMed

Browning LM, Hsieh SD, Ashwell M (2010)

A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes

Nutrition Research Reviews

Key finding: Systematic review confirming 0.5 threshold across 78 studies

View on PubMed

Begley CG, Ellis LM (2012)

Drug development: Raise standards for preclinical cancer research

Nature

Key finding: Only 11 of 53 (21%) landmark cancer studies could be replicated

View on PubMed

Ioannidis JPA (2005)

Why most published research findings are false

PLoS Medicine

Key finding: Theoretical and empirical argument that majority of research findings are false

View on PubMed

Open Science Collaboration (2015)

Estimating the reproducibility of psychological science

Science

Key finding: Only 36% of psychology studies replicated

View on PubMed

See also

Evidence grades are informational and do not replace medical advice.